KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by high rates of recurrence and poor overall survival. This is due, in part, to a deficiency of targeted therapies, making it essential to identify therapeutically targetable driver pathways of this disease. While epidermal growth fac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Roberts, Melyssa S., Anstine, Lindsey J., Finke, Viviane S., Bryson, Benjamin L., Webb, Bryan M., Weber-Bonk, Kristen L., Seachrist, Darcie D., Majmudar, Parth R., Keri, Ruth A.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7301986/
https://ncbi.nlm.nih.gov/pubmed/32552913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01305-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados